Real-World Evidence (RWE) and
Late Phase Research Studies
“We support pharmaceutical companies to effectively meet the growing real-world data requirements with observational studies for better outcomes or greater value”
Our ethos is to encourage original scientific thought and innovation so that projects benefit from the best design and execution.
1
PRIMARY/ FIELD STUDIES
We work seamlessly with our partners to ensure that the specific requirements of real-world evidence are met in the most cost-effective way.
2
SECONDARY DATABASE STUDIES
We understand that matching research objectives with the capabilities of local data sources is an essential step in undertaking valid and credible research.
3
HYBRID STUDIES
We combine elements of different study designs and data sources to maximise balance of validity, reliability, efficiency, costs and practicality and build a bespoke approach tailored to study objectives.
PRIMARY/FIELD STUDIES
OXON offers single and multi-country primary data collection studies (Cohort, Case Control, Cross-Sectional and Surveys) using retrospective, prospective and cross-sectional data collection methodologies for safety, Market Access/HEOR and Drug Development.
DATABASE STUDIES
OXON provides clients with single and multi-country database studies (Cohort, Case Control, Cross-Sectional) using secondary data sources to satisfy client’s requirements for safety, Market Access/HEOR and Drug Development.
HYBRID STUDIES
OXON supports sponsors to fill evidence gaps and generate RWE through the most valid, reliable, efficient, cost-effective, and practical hybrid approaches. Our ability to combine data collection with secondary data allows an accurate approach to study objectives.
Observational Research Study Designs
OXON provides a unique blend of observational science and operational excellence to our clients as fellow scientists.
The objective of most clinical studies is to determine prevalence, incidence, cause, prognosis, or effect of treatment, being certain types of studies most commonly associated with each objective.
At OXON we advise clients frankly on the advantages and disadvantages of their observational study options while our experts help determine the right type of study according to the time, cost, and regulatory implications.
VALIDATION
STUDIES
OXON specializes in conducting comprehensive validation studies that assess and enhance the quality of secondary data used in research.
PASS & PAES
STUDIES
We assist our clients in designing and conducting post-authorisation safety/efficacy secondary data or data collection studies in Europe, USA and globally.
RMS AND CONTROLLED & EARLY ACCESS PROGRAMMES
OXON designs, implements, and evaluates RMMs globally. We also use controlled and early access programmes to understand how therapies are used in real-world settings and the patients who benefit from them.
SYSTEMATIC REVIEWS
& META-ANALYSIS
Using systematic methods, we identify, appraise, and synthesize the best available evidence, employing appropriate statistical techniques to combine data.
PATIENT REGISTRIES
Patient disease registries offer real-world insights into clinical practice, patient outcomes, and safety, informing clinical decision-making. Our EDC platform supports both new and existing registries globally.
PRAGMATIC TRIALS
Design and execution of pragmatic, simplified, and cost-effective trials, of drugs, vaccines, devices, diagnostics and educational materials and guidelines, bridging the gap between clinical trials and RWE.
MARKET ACCESS/HEOR
Expertise in health economics and patient-reported outcomes within observational studies to help collect the evidence needed to prove the cost-effectiveness & cost-utility of drugs required by stakeholders.
PATIENT-REPORTED OUTCOMES
Incorporating PROs into RWE initiatives ensures a more comprehensive understanding of treatment impacts, leading to better patient outcomes and more effective healthcare strategies.